Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Neuropsychology

Living with CPA: Monitoring and Quality of Life

At a Glance

People living with cerebral proliferative angiopathy need individualized imaging and blood-flow monitoring, symptom tracking, and support for anxiety and fatigue. Sudden weakness, speech or vision changes, confusion, thunderclap headache, or prolonged seizures require calling 911.

Living with Cerebral Proliferative Angiopathy (CPA) is a journey of ongoing partnership with your medical team. Because this condition is characterized by a “proliferative” (growing) nature, it is not always stable over time [1][2]. Regular monitoring is not just a precaution; it is a proactive strategy to ensure your brain’s blood supply remains adequate and to catch any high-risk changes, such as new aneurysms, before they cause problems [3][4].

The Monitoring Framework

There is no “one-size-fits-all” schedule for CPA because every patient’s vascular network behaves differently. Your doctors will create an individualized plan based on your symptoms and the specific features of your scans [5][6].

  • Surveillance Imaging: You will likely have an MRI or MRA at individualized intervals—for example, some teams use 6 to 12 months initially, though this depends entirely on your symptoms and prior procedures [5][3].
  • Perfusion and Reserve Testing: Your team may use specialized scans like SPECT or Arterial Spin Labeling (ASL) to measure your baseline cerebral blood flow; assessing cerebrovascular reserve (your brain’s ability to “turn up the volume” on blood flow) usually requires an additional challenge like acetazolamide [2][7].
  • Selective Angiography: A repeat Digital Subtraction Angiography (DSA) is typically not done every year. It is usually reserved for when non-invasive scans show a significant change or if a new “culprit lesion” (like an aneurysm) is suspected [1][8].

Managing “Scanxiety”

It is completely normal to feel a surge of anxiety in the days or weeks leading up to a follow-up scan—a phenomenon often called scanxiety [9]. Studies in similar vascular conditions show that up to 66% of patients experience this emotional strain [9].

To help manage this:

  • Request Early Results: Anxiety often peaks while waiting for a report. Ask your team if you can schedule a “results call” or a portal message for the same day or the day after the scan [9].
  • Gather Information: Knowing exactly what the procedure will involve and how long it will take can lower your baseline stress [10][11].
  • Distraction and Support: Plan a treat or an engaging activity for the afternoon after your scan, and bring a trusted friend or family member to your appointment if possible [12][13].

Navigating Day-to-Day Life

Living with CPA often means managing chronic “invisible” symptoms. Maintaining your quality of life requires a focus on both physical and mental well-being.

  • Headaches and Fatigue: Some patients report cognitive fatigue (a feeling of “brain fog” after mental tasks) and chronic headaches [14][15]. Pacing your activities and ensuring high-quality sleep can help manage these energy drains [16].
  • Physical Activity: While regular exercise is generally good for vascular health, you should ask your doctor for individualized guidance regarding gradual physical activity, blood pressure control, and hydration [17][18]. Do not self-impose severe exercise restrictions or change blood-pressure medications without your doctor’s guidance.
  • Cognitive Health: Because some patients report that CPA can affect memory or processing speed, consider requesting a clinical assessment or a baseline neuropsychological evaluation [14]. This gives your team a clear “map” of your cognitive strengths to compare against in the future.
  • Symptom Tracking: Keep a simple log of your symptoms. A “new” symptom is often more important than a “chronic” one. If a headache feels different, contact your team. However, for sudden weakness, speech/vision changes, confusion, thunderclap headaches, or prolonged seizures, call 911 immediately—these require emergency services [19][20].

By staying consistent with your monitoring and being vocal about your symptoms, you and your care team can make informed adjustments to your care plan, keeping your brain’s health as the top priority [21][22].

Common questions in this guide

How often should I have MRI or MRA scans for CPA?
There is no single monitoring schedule for cerebral proliferative angiopathy. Some teams use MRI or MRA at intervals of 6 to 12 months initially, but the timing should be based on your symptoms, scan findings, and any prior procedures.
How is blood flow monitored in cerebral proliferative angiopathy?
MRI or MRA can monitor the brain’s vascular network, while SPECT or arterial spin labeling, also called ASL, may measure baseline brain blood flow. Testing cerebrovascular reserve—the brain’s ability to increase blood flow when needed—usually requires an added challenge with acetazolamide.
When would I need a repeat DSA for CPA?
A repeat digital subtraction angiography, or DSA, is not usually performed every year. It is generally considered when noninvasive imaging shows a significant change or when a new problem, such as an aneurysm, is suspected.
What can I do about anxiety before a CPA scan?
Scan-related anxiety is common. Ask whether you can receive results by phone or through a patient portal soon after the scan, learn what the procedure will involve, and arrange a calming activity or support person for the day.
What CPA symptoms require emergency help?
Call 911 immediately for sudden weakness, speech or vision changes, confusion, a thunderclap headache, or a prolonged seizure. A new or noticeably different headache that is not an emergency should still be reported to your medical team.
Could a neuropsychological evaluation help me track cognitive changes?
A neuropsychological evaluation can establish a baseline of memory, processing speed, and other cognitive strengths. Your team can compare future results with that baseline if you notice brain fog or other cognitive changes.
Are there exercise or blood pressure restrictions with CPA?
Restrictions should be individualized by your care team. Ask about gradual activity, high-intensity exercise, blood pressure control, and hydration, and do not change blood-pressure medicines or impose severe exercise limits without medical guidance.

Get notified when new evidence is published on Cerebral proliferative angiopathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (22)
  1. 1

    Long-term hemodynamic changes in cerebral proliferative angiopathy presenting with intracranial hemorrhage: illustrative case.

    Saito T, Harada K, Kajihara M, et al.

    Journal of neurosurgery. Case lessons 2023; (5(16)).

    PMID: 37070681
  2. 2

    Progressive Cerebral Ischemia and Intracerebral Hemorrhage after Indirect Revascularization for a Patient with Cerebral Proliferative Angiopathy.

    Kimiwada T, Hayashi T, Takahashi M, et al.

    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 2019; (28(4)):853-858 doi:10.1016/j.jstrokecerebrovasdis.2018.11.021.

    PMID: 30737070
  3. 3

    Development of Abnormal Hemispheric Vascular Networks Mimicking Cerebral Proliferative Angiopathy in a Child Originally Diagnosed with Deep-Seated Arteriovenous Fistula.

    Sakata H, Fujimura M, Sato K, et al.

    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 2016; (25(10)):e200-4.

    PMID: 27554072
  4. 4

    De novo ruptured intracranial aneurysm associated with cerebral proliferative angiopathy: illustrative case.

    Suetsugu H, Okawa S, Ishibashi T, et al.

    Journal of neurosurgery. Case lessons 2026; (12(7)).

    PMID: 42607334
  5. 5

    Cerebral proliferative angiopathy accompanied by cerebral cavernous malformation: A case report.

    Engin EF, Polat B, Ertan Akan G, Akgül E

    Clinical neurology and neurosurgery 2021; (210()):107011 doi:10.1016/j.clineuro.2021.107011.

    PMID: 34741975
  6. 6

    Pediatric cerebral proliferative angiopathy presenting infratentorial hemorrhage.

    Beniwal M, Kandregula S, Aravind , et al.

    Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 2020; (36(2)):429-433 doi:10.1007/s00381-019-04313-x.

    PMID: 31338577
  7. 7

    Evaluating Vascular Hemodynamics in Cerebral Proliferative Angiopathy Using Advanced Arterial Spin Labeling MRI.

    Duarte Armindo R, Zhao M, Alexander S, et al.

    Stroke (Hoboken, N.J.) 2025; (5(2)):e001552 doi:10.1161/SVIN.124.001552.

    PMID: 41573183
  8. 8

    Multiple Endovascular Treatments for Hemorrhagic Cerebral Proliferative Angiopathy: A Case Report.

    Shomura K, Kamide T, Misaki K, et al.

    Case reports in neurology 2022; (14(3)):433-440 doi:10.1159/000527559.

    PMID: 36636273
  9. 9

    Scanxiety and quality of life around follow-up imaging in patients with unruptured intracranial aneurysms: a prospective cohort study.

    Kamphuis MJ, van der Kamp LT, van Eijk RPA, et al.

    European radiology 2024; (34(9)):6018-6025 doi:10.1007/s00330-024-10602-0.

    PMID: 38311702
  10. 10

    Effect of information delivery techniques in reducing pre-procedural anxiety in computed tomography.

    Ahmed HS, Gupta D, Aluru DR, et al.

    Current problems in diagnostic radiology 2024; (53(6)):723-727 doi:10.1067/j.cpradiol.2024.07.015.

    PMID: 39019712
  11. 11

    Biomarkers and Psychological Factors Associated with Distress in Children, Adolescents, and Young Adults Undergoing MRI Neuroimaging: A Systematic Review of Observational Studies with Clinical Recommendations.

    Ceniza-Bordallo G, Del Pino AB, Soldic D, Torrado-Carvajal A

    Healthcare (Basel, Switzerland) 2026; (14(9)) doi:10.3390/healthcare14091160.

    PMID: 42121603
  12. 12

    Prevalence, severity, and modifiable predictors of scanxiety in patients undergoing routine oncologic imaging: a prospective longitudinal study.

    Shah MS, Memon JA, Malik U, et al.

    Clinical imaging 2025; (128()):110634 doi:10.1016/j.clinimag.2025.110634.

    PMID: 41077027
  13. 13

    Scanxiety: a scoping review about scan-associated anxiety.

    Bui KT, Liang R, Kiely BE, et al.

    BMJ open 2021; (11(5)):e043215 doi:10.1136/bmjopen-2020-043215.

    PMID: 34039571
  14. 14

    Towards a neurocognitive profile in familial cerebral cavernous malformations.

    Silva C, Durães J, Lima M, et al.

    Acta neurologica Belgica 2024; (124(1)):49-54 doi:10.1007/s13760-023-02314-x.

    PMID: 37392320
  15. 15

    Natural history of cerebral cavernous malformations.

    Ene C, Kaul A, Kim L

    Handbook of clinical neurology 2017; (143()):227-232 doi:10.1016/B978-0-444-63640-9.00021-7.

    PMID: 28552144
  16. 16

    Encephaloduroarteriomyosynangiosis with the middle meningeal artery for proliferative cerebral angiopathy treatment: A case report.

    Xochipa-Ruiz KE, Lara-Torres F, Casas-Martínez MR, et al.

    Surgical neurology international 2025; (16()):438 doi:10.25259/SNI_855_2025.

    PMID: 41216168
  17. 17

    Antithrombotic therapy and risk of intracranial hemorrhage in patients with cerebral cavernous malformations: a multicenter propensity-matched cohort study.

    Salim HA, Lakhani DA, Hajjeh O, et al.

    Journal of neurology 2026; (273(6)).

    PMID: 42240840
  18. 18

    Long-term antithrombotic therapy and risk of intracranial haemorrhage from cerebral cavernous malformations: a population-based cohort study, systematic review, and meta-analysis.

    Zuurbier SM, Hickman CR, Tolias CS, et al.

    The Lancet. Neurology 2019; (18(10)):935-941 doi:10.1016/S1474-4422(19)30231-5.

    PMID: 31401075
  19. 19

    Familial Multiple Cavernous Malformation Syndrome: MR Features in This Uncommon but Silent Threat.

    Mespreuve M, Vanhoenacker F, Lemmerling M

    Journal of the Belgian Society of Radiology 2016; (100(1)):51 doi:10.5334/jbr-btr.938.

    PMID: 30151459
  20. 20

    Systematic review of pediatric cerebral proliferative angiopathy.

    Yamaki VN, Alwis A, Chowdhury SS, et al.

    Journal of neurosurgery. Pediatrics 2026; 1-13 doi:10.3171/2026.4.PEDS25435.

    PMID: 42854234
  21. 21

    Cerebral proliferative angiopathy in pediatric patients: case-based review with an illustrative case.

    Moskalik AD, Mo J, Sawyerr M, et al.

    Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 2026; (42(1)):62 doi:10.1007/s00381-026-07129-8.

    PMID: 41652190
  22. 22

    A Proposed Algorithm for Managing Cerebral Proliferative Angiopathy.

    Chen YN, Lee CW, Xiao F, et al.

    World neurosurgery 2022; (167()):e360-e369 doi:10.1016/j.wneu.2022.08.009.

    PMID: 35961587

This page is for informational purposes only and does not constitute medical advice. Your treating team should individualize your imaging schedule, activity guidance, blood pressure plan, and response to symptoms.

Guide contents Cerebral proliferative angiopathy
Research & Literature
05 Building Your Care Team